Compass Pathways (NASDAQ:CMPS), a leader in psychedelic-assisted therapies, receives a significant boost as analysts upgrade its rating to Buy with a price target of $14 per share. This move reflects optimism around the company’s Phase 3 clinical programs targeting mental health disorders.
Stock Performance and Valuation
The stock trades around $9.06, marking a 15% year-to-date gain and an impressive 113% rise over the past year. Despite recent surges, current valuations suggest the shares remain undervalued. The company’s market capitalization stands at approximately $1.14 billion, while it records a trailing 12-month negative EBITDA of about $175 million.
Phase 3 Trial Momentum
Analysts highlight the progress in the largest-ever three-year Phase 3 programs for psilocybin-based therapies, COMP005 and COMP006. Positive safety data from prior Phase 2 studies supports expectations for pivotal Phase 3 outcomes. Recent results from COMP006 Part A demonstrate strong efficacy signals, while COMP005 Part B reveals promising safety profiles.
COMP006’s 26-week data anticipates release in Q1 2026, potentially paving the way for a new drug application (NDA) filing. These developments underscore a critical juncture for the company’s pipeline advancement.
Market Potential and Competitive Edge
Psilocybin therapies offer safe, effective alternatives to treatments like transcranial magnetic stimulation (TMS) when combined with structured therapy. Research collaborations with prestigious institutions, including Stanford, Harvard, and Johns Hopkins universities, bolster data credibility and attract investors.
Beyond depression, these therapies target breakthroughs in post-traumatic stress disorder (PTSD). Compass Pathways leads with COMP360, a psilocybin formulation in late-stage development for treatment-resistant depression. U.S. government grants support educational content and key agency initiatives, positioning the company among top contenders.
Analyst Consensus
Other firms echo the positive outlook. Canaccord maintains a Buy rating but adjusts its price target to $18 from $20. H.C. Wainwright holds Buy at $70, citing robust fundamentals through Q4 2026 NDA progress. Stifel upgrades to Buy with a $14 target, factoring in 2025 Q4 NDA milestones.
Investors eyeing deeper insights into CMPS alongside broader U.S. listings can explore comprehensive research tools for informed decisions.
